



ALK
Investor Relations Department
BÃge Alle 6-8
Horsholm DK-2970
Denmark

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

OMX: ALKB

Last Trade:	744.00
Trade Time:	4:59 PM ET Dec 8, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	681.00 - 1133.00
Volume	3,993,200

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

Company releases [\[View all \]](#)

Dec 7, 2017

[Report on transactions with ALK-Abell A/S B-shares and associated securities by managerial staff](#)

Dec 7, 2017

[Indberetning af ledelsens transaktioner med ALK-Abell A/S' B-aktier og tilknyttede vrdipapirer](#)

Dec 7, 2017

[PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELL A/S](#)

Dec 6, 2017

[ALK-ABELL A/S TO ISSUE UP TO 92,076 AA SHARES AND UP TO 920,760 B SHARES IN A PRIVATE PLACEMENT](#)

Dec 4, 2017

[ALK launches ambitious, transformational growth strategy](#)